We recommend designing neoadjuvant/adjuvant window of opportunity trials for GBM patients who are positive for mutant EGFR, using next-generation therapeutics targeting EGFR, such as JCN037, an irreversible TKI specifically designed for CNS neoplasms [13, 47]. This evidence concerns the gene EGFR and glioblastoma.